Articles from Amplitude Vascular Systems

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, presented the results of the first 95 patients treated in the POWER PAD II U.S. pivotal study for Pulsatile Intravascular Lithotripsy (PIVL) therapy as a Late Breaking Clinical Trial (LBCT) at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas, NV. Principal Investigator, Dr. Chris Metzger, Interventional Cardiologist at Ballad Health in Kingsport, TN, presented the results from the prospective, single-arm study designed to assess the safety and efficacy of AVS’s Pulse IVL™ System for the treatment of patients with moderate to severely calcified peripheral arterial disease.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced its schedule of events for the upcoming Transcatheter Cardiovascular Therapeutics (TCT) and Vascular InterVentional Advances (VIVA) meetings.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today the opening of its new global headquarters at 180 Third Avenue in Waltham, Mass. The new 37,811 square-foot space will serve as the company’s hub for innovation, operations and commercialization, supporting company growth and further development of its novel device for pulsatile intravascular lithotripsy (PIVL), the PULSE™ IVL System.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it will present 30-day results of its POWER PAD II U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy as a Late Breaking Clinical Trial (LBCT) at the Vascular InterVentional Advances (VIVA) meeting in November. The POWER PAD II clinical study was designed to evaluate the safety and efficacy of AVS’s Pulse IVL™ System for the treatment of patients with moderate to severely calcified peripheral arterial disease in the United States. Chris Metzger, M.D., Interventional Cardiologist at Ballad Health in Kingsport, Tenn., is the National Principal Investigator of the POWER PAD II Trial.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M. The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™) device.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has enrolled the first patient(s) in its U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy. The POWER PAD II clinical study will evaluate the safety and efficacy of AVS’s Pulse IVL™ System for the treatment of patients with moderate to severely calcified peripheral arterial disease. Nicolas W. Shammas, MD, FACS, FSCAI, FSVM, conducted the first case at UnityPoint Trinity Medical Center in Bettendorf, Iowa.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device innovation center in Buffalo, N.Y., led by Adnan Siddiqui, M.D. The partnership will execute clinical studies evaluating the Pulse IVL™ System in both Coronary and Carotid vasculatures and aims to expand clinical indications for the Pulse IVL System.